Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY (BMY)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/15/2018 05/16/2018 05/17/2018 05/18/2018 05/21/2018 Date
52.3(c) 52.21(c) 52.74(c) 52.71(c) 52.56 Last
8 133 051 5 417 361 8 097 423 6 440 125 2 741 830 Volume
+0.54% -0.17% +1.02% -0.06% -0.28% Change
More quotes
Financials (USD)
Sales 2018 21 726 M
EBIT 2018 5 509 M
Net income 2018 4 503 M
Finance 2018 428 M
Yield 2018 3,09%
Sales 2019 23 004 M
EBIT 2019 6 076 M
Net income 2019 5 498 M
Finance 2019 2 537 M
Yield 2019 3,19%
P/E ratio 2018 19,03
P/E ratio 2019 16,01
EV / Sales2018 3,95x
EV / Sales2019 3,64x
Capitalization 86 206 M
More Financials
Company
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products.It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics.The company was... 
Sector
Pharmaceuticals
Calendar
05/22 | 05:30pmPresentation
More about the company
Surperformance© ratings of Bristol-Myers Squibb Compa
Trading Rating : Investor Rating :
More Ratings
Latest news on BRISTOL-MYERS SQUIBB COMPA
01:03pBRISTOL MYERS SQUIBB : to Take Part in UBS 2018 Global Healthcare Conference
AQ
01:02pBiohaven pharmaceuticals reports first quarter 2018 financial and recent busi..
AQ
01:02pBRISTOL MYERS SQUIBB : Highlights Breadth of Immuno-Oncology-Based Combination R..
AQ
05/18AstraZeneca insists future is bright after big Crestor sales hit
RE
05/17BRISTOL MYERS SQUIBB : Trademark Application for "I CAN WITH RA" Filed by Bristo..
AQ
05/17BRISTOL MYERS SQUIBB : Findings in the Area of Proteins Reported from Bristol-My..
AQ
05/17BRISTOL MYERS SQUIBB : Recent Findings in Laboratory Research Described by Resea..
AQ
05/17BRISTOL MYERS SQUIBB : Studies from Bristol-Myers Squibb Co. in the Area of Porp..
AQ
05/17Jounce sags after ICOS mAb readout
AQ
05/17CELLDEX THERAPEUTICS : Provides Corporate Update and Reports First Quarter 2018 ..
AQ
More news
Sector news : Pharmaceuticals - NEC
12:40pASTRAZENECA : potassium drug finally approved, threatening Vifor
RE
12:35pEU Approves GlaxoSmithKline JV's Juluca HIV Treatment
DJ
11:57aMERCK AND : Ebola Vaccine Arrives in Democratic Republic of Congo
DJ
09:01aRoche Presents Positive Results From Hemlibra Trials
DJ
08:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on BRISTOL-MYERS SQUIBB COMPA 
BRISTOL-MYERS SQUIBB CO - 2016
Attractive price levels
BUY
More Strategies
Latest Tweets
11:49a$BMY $CELG $JNCE  
09:07a$BMY $MRK $SNDX  
05/20$BMY is Bullish above $52.71. Trade near $52.71  
05/20ICYMI: Loxo gains, Jounce drops after releasing abstracts for #ASCO18. $LOXO ..
7
05/18$AZN might look at TMB in Neptune - whose readout just got delayed to 2019 so..
2
More tweets
Qtime:196
News from SeekingAlpha
05:49aJounce Therapeutics Tumbles On ASCO Reveal, Is There Salvageable Data? 
03:07aSyndax Falls On ASCO Abstract Results, But Was Its Drop Justified At This Tim.. 
05/203 THINGS IN BIOTECH, MAY 19 : Buy BMY? Oncolytics In Again? Atara's Immunotherap.. 
05/18This May Be The Best Time To Pick Up Exelixis In 2018 
05/18Investors bullish on biotechs after Trump drug pricing speech 
Chart BRISTOL-MYERS SQUIBB COMPA
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 22
Average target price 58,3 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-13.94%86 206
JOHNSON & JOHNSON-11.08%332 184
PFIZER-1.41%212 424
NOVARTIS-6.55%202 969
ROCHE HOLDING LTD.-8.90%193 622
MERCK AND COMPANY5.10%158 916